Eli Lilly's acquisition spree shows no sign of stalling, although the Big Pharma is keeping the terms of its latest buy ...

Callio Therapeutics is developing novel dual-payload antibody-drug conjugates (ADCs) designed to address resistance to existing cancer therapies, ...

CrossBridge Bio, Inc., a pre-clinical biotechnology company pioneering the development of next-generation dual-payload ...

Worth up to $300 million, the buyout is Lilly’s latest of an ADC maker and adds technology for making “dual-payload” ...

OBI Pharma is a clinical-stage global oncology company established in 2002 and headquartered in Taiwan. Together with its subsidiary OBI Pharma USA, Inc., the company is dedicated to developing ...

Three years after its OrbiMed-backed series A in 2023, Sidewinder Therapeutics is adding to its nest egg courtesy of a clutch ...

According to MarketsandMarkets(TM), the Next Generation Drug Conjugates Market is projected to grow from about USD 15.75 billion in 2026 to USD 42.55 billion by 2035, at a CAGR of 11.7%. Browse 260 ...

Roche is paying $20 million upfront to secure rights to two degrader-antibody conjugates (DACs), developed by longtime ...

The market opportunities in the Antibody Drug Conjugate (ADC) space are centered around the advancement of novel ADCs addressing unmet needs in targeted cancer therapy. Innovations in payloads, ...

DUBLIN--(BUSINESS WIRE)--The "Bispecific Antibody Drug Conjugates Clinical Trials, Development Platforms, Competitive Landscape & Market Opportunity Insight 2025" report has been added to ...